- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
FDA Approves Biocon Biologics' Bevacizumab Biosimilar
Biocon Biologics expands its oncology biosimilar roster after gaining FDA approval for Jobevne (bevacizumab-nwgd), the sixth biosimilar referencing Avastin (bevacizumab).
The present approval adds to the company’s growing oncology portfolio in the US, which already includes Ogivri (trastuzumab-dkst) for HER2-positive breast cancer and Fulphila (pegfilgrastim-jmdb) to reduce the risk of febrile neutropenia in patients undergoing chemotherapy. | Image Credit: gguy - stock.adobe.com .jpeg
Biocon Biologics expands its oncology biosimilar roster after gaining FDA approval for Jobevne (bevacizumab-nwgd), the sixth biosimilar referencing Avastin (bevacizumab).1,2
The new recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF) receptors is indicated for the treatment of colorectal cancer, non–small cell lung cancer, glioblastoma, renal cell carcinoma, and cervical cancer, ovarian, fallopian tube, and primary peritoneal cancers.1
"The U.S\ FDA approval of Jobevne (bevacizumab-nwgd) is a significant milestone—our seventh biosimilar approved in the US and a strong addition to our robust oncology portfolio. It underscores the depth of our scientific expertise and commitment to expanding access to high-quality, affordable biologics. We look forward to working with all stakeholders to bring more treatment options to patients," commented Shreehas Tambe, CEO and managing director, Biocon Biologics, in a statement.
In addition to cancer indications, reference bevacizumab (Avastin) is often used off label for age-related macular degeneration, diabetic macular edema, retinal vein occlusions, neovascular glaucoma, corneal vascularization, pterygium, and after trabeculectomy to prevent bleb failure.3 Biosimilars could provide greater access to biosimilar therapies for these conditions as well.
Jobevne joins 5 other Avastin competitors: Celltrion's Vegzelma (bevacizumab-adcd), Amgen/Allergan's Mvasi (bevacizumab-awwb), Pfizer's Zirabev (bevacizumab-bvzr), Amneal Pharmaceuticals/Kashiv Biosciences Alymsys (bevacizumab-maly), and Sandoz/Bio-Thera Solutions' Avzivi (bevacizumab-tnjn).2
The present approval adds to the company’s growing oncology portfolio in the US, which already includes Ogivri (trastuzumab-dkst) for HER2-positive breast cancer and Fulphila (pegfilgrastim-jmdb) to reduce the risk of febrile neutropenia in patients undergoing chemotherapy.1 The biosimilar has also been approved in Europe and Canada, where it's marketed under the brand name Abevmy.2
In addition to its oncology biosimilars, the company has made significant strides in diabetes care with the launch of Semglee (insulin glargine-yfgn), the first interchangeable biosimilar approved in the US.4 With products in over 120 countries and a pipeline packed with 20 biosimilars in development across different therapeutic areas, the company said it is keeping its focus on making high-quality biologics more accessible and affordable for people around the world.
References
1. Biocon Biologics announces U.S. FDA approval for Jobevne, biosimilar bevacizumab, expanding Its oncology portfolio. Press release. Biocon Biologics; April 10, 2025. Accessed April 10, 2025. https://www.biocon.com/biocon-biologics-announces-u-s-fda-approval-for-jobevne-biosimilar-bevacizumab-expanding-its-oncology-portfolio/
2. Biosimilar approvals. The Center for Biosimilars®. Updated April 10, 2025. Accessed April 10, 2025. https://www.centerforbiosimilars.com/biosimilar-approvals
3. Singh S, Saxena S, Akduman L, Meyer CH. Off-label use of intravitreal bevacizumab: a global conundrum. Indian J Ophthalmol. 2024;72(5):617-619. doi:10.4103/IJO.IJO_2166_23
4. Hagen T. FDA approves Semglee insulin glargine as first interchangeable biosimilar. The Center for Biosimilars. July 28, 2021. Accessed April 10, 2025. https://www.centerforbiosimilars.com/view/fda-approves-semglee-insulin-glargine-as-first-interchangeable-biosimilar
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
